Service de MédecineNucléaire, EA 3878 (GETBO) IFR 148, Centre Hospitalo-Universitaire de Brest, Université de Bretagne Occidentale, 2, avenue Foch, 29609 Brest, Cedex, France.
Service de MédecineNucléaire, EA 3878 (GETBO) IFR 148, Centre Hospitalo-Universitaire de Brest, Université de Bretagne Occidentale, 2, avenue Foch, 29609 Brest, Cedex, France.
Thromb Res. 2017 Nov;159:48-51. doi: 10.1016/j.thromres.2017.08.021. Epub 2017 Sep 28.
Venous thromboembolism (VTE) can occur as the first manifestation of an underlying occult malignancy. It remains unclear whether or not a better selection of high risk patients might lead to more efficient occult cancer screening strategies. Our aim was to assess the predictors of occult malignancy diagnosis in patients with unprovoked VTE. Univariate analyses were performed to assess the effect of candidate predictors on occult cancer detection in patients enrolled in a prospective, multicenter, randomized, controlled study (MVTEP study) whose primary aim was to compare a limited screening strategy with a strategy combining limited screening and FDG PET/CT in patients with unprovoked VTE. This trial is completed and registered with ClinicalTrials.gov, number NCT00964275. Between March 3, 2009, and August 18, 2012, 399 patients were included. Five patients withdrew consent and refused the use of their data, and no VTE was confirmed in 2 patients who were excluded from this analysis. A total of 25 (6.4%) out of the 392 analysed patients received a new diagnosis of malignancyduring the 2-years follow-up. Age≥50years (p=0.01), male gender (p=0.04), leukocytes count (p=0.01), and platelets count (p=0.03) were associated with occult cancer detection. Patients with leukocytosis or thrombocytosis had a risk of cancer way above 10%. Previous VTE and smoker status (combining previous and current smokers) were not associated with occult cancer diagnosis (p>0.05). Demographic characteristics (age and sex), and laboratory tests (high platelets and leukocytes counts) may be associated with cancer detection in patients withunprovoked VTE.
静脉血栓栓塞症 (VTE) 可作为潜在隐匿性恶性肿瘤的首发表现。目前尚不清楚是否更好地选择高危患者可能会导致更有效的隐匿性癌症筛查策略。我们的目的是评估在无诱因 VTE 患者中隐匿性恶性肿瘤诊断的预测因素。进行单因素分析以评估候选预测因素对纳入前瞻性、多中心、随机、对照研究(MVTEP 研究)的患者中隐匿性癌症检测的影响,该研究的主要目的是比较有限的筛查策略与在无诱因 VTE 患者中联合有限筛查和 FDG PET/CT 的策略。该试验已完成并在 ClinicalTrials.gov 上注册,编号为 NCT00964275。2009 年 3 月 3 日至 2012 年 8 月 18 日,共纳入 399 例患者。5 例患者撤回同意并拒绝使用其数据,2 例因未确诊 VTE 而被排除在本分析之外。在 2 年的随访期间,共 25 例(6.4%)分析患者确诊新的恶性肿瘤。年龄≥50 岁(p=0.01)、男性(p=0.04)、白细胞计数(p=0.01)和血小板计数(p=0.03)与隐匿性癌症检测相关。白细胞增多或血小板增多的患者患癌症的风险超过 10%。既往 VTE 和吸烟状况(包括既往和现在的吸烟者)与隐匿性癌症诊断无关(p>0.05)。在无诱因 VTE 患者中,人口统计学特征(年龄和性别)和实验室检查(高血小板和白细胞计数)可能与癌症检测相关。